spot_img
29 C
Philippines
Wednesday, November 27, 2024

COVID Briefs: FDA okays vax mix clinical trial

The Food and Drug Administration has approved the clinical trial on the combination of different COVID-19 vaccine brands for inoculation, an official said Friday.

The FDA approved the study and started screening applicants at its trial site in Marikina, said Rowena Guevara, Department of Science and Technology Undersecretary for Research and Development.

- Advertisement -

Some 3,000 participants are needed in the clinical trial, Guevara said.

DOH guidelines for booster out

A list of immunocompromised conditions eligible for an additional COVID-19 vaccine dose was released by the Department of Health on Friday.

Immunocompromised individuals with the following conditions are eligible for a third dose or a booster jab: autoimmune disease; HIV; cancer/malignancy; transplant patients; undergoing steroid treatment; and patients with poor prognosis/bed-ridden patients.

Some 4.2 million senior citizens and 7 million persons with comorbidities, along with members of their household, have so far been fully vaccinated against COVID-19, according to DOH data.

Manila rolls out third vax dose

The Manila Health Department started Friday its inoculation of COVID-19 booster shots of more than 1,200 fully-vaccinated health workers, or the priority group A1, of Manila City Hall in two vaccination sites in the city.

One vaccination site was at the Universidad de Manila and the other at the Aurora Elementary School.

Four vaccines— AstraZeneca, Moderna, Pfizer, and Sinovac—were already approved by the health department as booster shots.

Las Piñas follows suit this weekend

The Las Piñas city government said it will start administering COVID-19 vaccine booster shots for health workers this weekend.

City Health records showed 3,700 health workers belonging are scheduled to receive their booster shots today (Saturday) and tomorrow.

Only those who received their 2nd dose for at least six months are eligible for the shots. 

LATEST NEWS

Popular Articles